Published in Cancer Treat Rev on September 01, 1976
Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J Clin Invest (1980) 2.03
Oxidative and non-oxidative mechanisms in the inactivation of cardiac mitochondrial electron transport chain components by doxorubicin. Biochem J (1989) 1.07
Cardioprotective effect of curcumin against doxorubicin-induced myocardial toxicity in albino rats. Indian J Pharmacol (2012) 1.02
Doxorubicin (adriamycin) cardiomyopathy. West J Med (1983) 1.01
Systolic time interval as index of schedule--dependent doxorubicin cardiotoxicity in patients with acute myelogenous leukaemia. Br Med J (1979) 0.96
Cardiac disease induced by chronic adriamycin administration in dogs and an evaluation of vitamin E and selenium as cardioprotectants. Am J Pathol (1980) 0.94
Ultrastructural features of Adriamycin-induced skeletal and cardiac muscle toxicity. Am J Pathol (1985) 0.92
Cardiac damage induced by 2-amino-3-methyl-imidazo[4,5-f]quinoline in nonhuman primates. Environ Health Perspect (1994) 0.92
Cardiotoxicity in childhood cancer survivors: strategies for prevention and management. Future Cardiol (2012) 0.91
A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer. Br J Cancer (2002) 0.89
Reduced in vivo high-energy phosphates precede adriamycin-induced cardiac dysfunction. Am J Physiol Heart Circ Physiol (2010) 0.87
Use of anionic liposomes for the reduction of chronic doxorubicin-induced cardiotoxicity. Proc Natl Acad Sci U S A (1981) 0.87
Poly-L-aspartic acid as a carrier for doxorubicin: a comparative in vivo study of free and polymer-bound drug. Br J Cancer (1985) 0.84
Protective role of Phyllantus niruri extract in doxorubicin-induced myocardial toxicity in rats. Indian J Pharmacol (2011) 0.82
Rescue by coenzyme Q10 from electrocardiographic abnormalities caused by the toxicity of adriamycin in the rat. Proc Natl Acad Sci U S A (1978) 0.81
Prognostic role of troponin and natriuretic peptides as biomarkers for deterioration of left ventricular ejection fraction after chemotherapy. Arch Med Sci (2013) 0.81
Adriamycin and altered membrane functions in rat hearts. Br J Exp Pathol (1986) 0.80
Response kinetics of host and experimental solid tumour after adriamycin. Br J Cancer (1978) 0.79
Evaluation of free radical effects and catecholamine alterations in adriamycin cardiotoxicity. Am J Pathol (1984) 0.77
Resistance to adriamycin cytotoxicity among respiratory-deficient mutants in yeast. Antimicrob Agents Chemother (1980) 0.76
Cardioprotective Effect of Grape Seed Extract on Chronic Doxorubicin-Induced Cardiac Toxicity in Wistar Rats. Adv Pharm Bull (2016) 0.75
Adriamycin cardiotoxicity: report of an unusual case with features resembling endomyocardial fibrosis. J Clin Pathol (1981) 0.75
Painful-feet Syndrome among Prisoners of War. Br Med J (1946) 4.30
Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin. J Clin Oncol (1989) 1.81
Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol (1989) 1.44
Metabolic studies of Salbutanol-3H: a new bronchodilator, in rat, rabbit, dog and man. Eur J Pharmacol (1971) 1.41
New developments in the treatment of gastric carcinoma. Semin Oncol (1990) 1.32
Activity of adriamycin (NSC-123127) and daunomycin (NSC-82151) against mouse mammary carcinoma. Cancer Chemother Rep (1972) 0.94
Carboplatin: an active drug in metastatic breast cancer. J Clin Oncol (1992) 0.91
High dose folinic acid/etoposide/5-fluorouracil in advanced gastric cancer--a phase II study in elderly patients or patients with cardiac risk. Invest New Drugs (1990) 0.91
Phase I study of carboplatin given on a five-day intravenous schedule. J Clin Oncol (1983) 0.89
Cytotoxic effects of 1-beta-D-arabinofuranosyl-5-fluorocytosine and of 1-beta-D-arabinofuranosylcytosine in proliferating tissues in mice. Cancer Res (1969) 0.85
Mitomycin C in advanced breast cancer. Cancer Treat Rev (1985) 0.83
New developments in the treatment of gastric carcinoma. Cancer Treat Res (1991) 0.83
Distribution and metabolism of adriamycin in mice. Comparison with daunomycin. Rev Eur Etud Clin Biol (1972) 0.82
Doxorubicin-associated flare reactions. Oncol Nurs Forum (1990) 0.82
Effects of arabinosylcytosine nucleosides on DNA synthesis in rats. Cancer Res (1970) 0.82
Chemotherapy of gastric cancer. Cancer Treat Rev (1988) 0.81
Simultaneous radiotherapy and chemotherapy with carboplatin in inoperable squamous cell carcinoma of the head and neck: a phase II study. Cancer Invest (1992) 0.81
Current development of podophyllotoxins. Cancer Chemother Pharmacol (1982) 0.78
Etoposide and split-dose cisplatin in small-cell lung cancer. Am J Clin Oncol (1988) 0.78
Phase II study of carboplatin in untreated, inoperable non-small-cell lung cancer. Cancer Chemother Pharmacol (1990) 0.78
[Taxol (paclitaxel), first molecule of a new class of cytotoxic agents: taxanes]. Bull Cancer (1994) 0.78
Phase II study of carboplatin in untreated inoperable advanced stomach cancer. Eur J Cancer (1990) 0.77
Etoposide in patients with previously untreated non-small-cell lung cancer: a phase I study. Cancer Chemother Pharmacol (1991) 0.76
Phase II studies with carboplatin in non-small cell lung cancer. Semin Oncol (1990) 0.76
Purity profile of the indoloquinone anticancer agent EO-9 and chemical stability of EO-9 freeze dried with 2-hydroxypropyl-beta-cyclodextrin. Pharmazie (2008) 0.76
EO-9 bladder instillations: formulation selection based on stability characteristics and in vitro simulation studies. Int J Pharm (2006) 0.76
Biologic activity of some adriamycin (NSC-123127) derivatives. Cancer Chemother Rep (1975) 0.76
Carboplatin and radiotherapy in the treatment of head and neck cancer: six years' experience. Semin Oncol (1994) 0.75
Carminomycin (NSC-180024): a phase I study. Eur J Cancer (1980) 0.75
Carboplatin/etoposide as first-line chemotherapy in advanced ovarian carcinoma: a pilot study. Cancer Chemother Pharmacol (1991) 0.75
Combination chemotherapy with carboplatin, etoposide, and vincristine as first-line treatment in small-cell lung cancer. J Clin Oncol (1992) 0.75
Complexation study of the anticancer agent EO-9 with 2-hydroxypropyl-beta-cyclodextrin. Drug Dev Ind Pharm (2008) 0.75
Utilizing a participative analysis approach: the key to implementing a successful productivity monitoring system or cost accounting program--case study: emergency department. NLN Publ (1987) 0.75
5 House members talk about what was important. Am Nurse (1985) 0.75
Reducing surgical inventories through effective management: use of the microcomputer for inventory control. NLN Publ (1987) 0.75
Distribution and excretion of adriamycin in man. Biomedicine (1973) 0.75
The formation of a novel mercapturic acid during the metabolism of an N-methyl aromatic amine, 4-cyano-N,N-dimethylaniline. Biochem Pharmacol (1984) 0.75
[Distribution and chemotherapeutic activity of daunomycin and adriamycin in spontaneous mammary carcinoma of mice]. Tumori (1973) 0.75
Evaluation of a mass media community smoking cessation campaign. Addict Behav (1991) 0.75
Correlations between cytotoxicity, biochemical effects, drug levels, and therapeutic effectiveness of daunomycin and adriamycin on Sarcoma 180 ascites in mice. Cancer Res (1973) 0.75
Carboplatin/etoposide/vincristine therapy in small cell lung cancer. Oncology (1992) 0.75
On the reported lack of effectiveness of daunomycin (NSC-82151) and adriamycin (NSC-123127) on solid tumors. Cancer Chemother Rep (1972) 0.75
Gas-liquid chromatographic determination of salsolinol in the striatum of rat brain during the calcium carbimide--ethanol interaction. Can J Physiol Pharmacol (1983) 0.75
Clinical phase I trial of marcellomycin with a single-dose schedule. Eur J Cancer Clin Oncol (1983) 0.75
Megestrol acetate. Cancer Treat Rev (1983) 0.75
[Comparison of the in vitro and in vivo kinetic parameters of solid sarcoma 180]. Tumori (1973) 0.75
Paclitaxel in combination with weekly 24-hour infusional 5-fluorouracil plus leucovorin in the second-line treatment of metastatic breast cancer: results of a phase II study. Ann Oncol (1998) 0.75
State of professional association: President's address. Chart (1985) 0.75
Tumors and dental and ocular abnormalities after treatment of infant rats with adriamycin. Tumori (1978) 0.75
Phase II study of carboplatin/ifosfamide in untreated advanced cervical cancer. Cancer Chemother Pharmacol (1990) 0.75
'Gobsmacking grins'. Br Dent J (1991) 0.75
[Cell proliferation kinetics in ascites sarcoma 180]. Tumori (1973) 0.75
Cytotoxic, antiviral, and antitumor activity of some derivatives of daunomycin (NSC-82151). Cancer Chemother Rep (1974) 0.75
[Study of high doses of carboplatin as a first choice in the therapy of advanced ovarian cancers]. Bull Cancer (1991) 0.75
n-Butylglycidyl ether: the formation of a novel metabolite of an epoxide. Drug Metab Dispos (1985) 0.75
Phase II and III studies with carboplatin in small cell lung cancer. Semin Oncol (1992) 0.75
Development and utilization of a microcomputer-based financial feasibility management model in planning for new or expanded ambulatory care programs. NLN Publ (1987) 0.75
Voltammetric reduction of nickel and cobalt dimethylglyoximate. Anal Chem (1996) 0.75
Carboplatin in small cell lung cancer. Semin Oncol (1991) 0.75
Dental health attitudes in Somerset: report of a dental health activity, 1985. Dent Health (London) (1987) 0.75
New platinum complexes in clinical trials. Cancer Treat Rev (1983) 0.75
A survey of breast feeding. Practitioner (1971) 0.75